Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) FCF Margin (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed FCF Margin for 7 consecutive years, with 41.44% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 6110.0% to 41.44% in Q4 2025 year-over-year; TTM through Dec 2025 was 19.83%, a 23389.0% increase, with the full-year FY2025 number at 19.83%, up 23389.0% from a year prior.
  • FCF Margin was 41.44% for Q4 2025 at Madrigal Pharmaceuticals, down from 27.5% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 27.5% in Q3 2025 to a low of 922.78% in Q2 2024.